389P Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial

Han Li(Hebei Medical University), Zhi Shi(University of Jinan), G. ren(Shandong First Medical University), Shujuan Sun(Shandong First Medical University), Z. Yv(Binzhou Medical University), Binkui Li(Sun Yat-sen University), Biao Fan(Shandong Tumor Hospital), Lingling Wang(SLAC National Accelerator Laboratory), Zhan Wang(First Affiliated Hospital of Zhengzhou University), Xuan Zhao(People's Hospital of Xinjiang Uygur Autonomous Region), Weiling Li(Shandong University), Jie Huang(Shandong First Medical University), Dongdong Zhou(Shandong Tumor Hospital), Haiying Fu(Jilin University), Xiu‐Lan Sun(Nanjing University of Chinese Medicine), Shu Fang(Peking University), Yiqiu Liao(Nanchang University)
Annals of Oncology
September 1, 2024
Cited by 0


Related Papers